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Abstract
Purpose Medicines regulatory authorities advise that patient information leaflets (PILs) should provide specific advice on what
actions to take if one or more doses are missed. We aimed to assess the content in this regard, of PILs and Summaries of Product
Characteristics (SmPCs) of prescription only medicines (POMs) marketed in the UK.
Methods PILs and SmPCs were accessed via the electronic Medicines Compendium. The following terms were used in the
advanced search facility: miss(ed), omit(ted), adhere(d), delay(ed), forgot, forget, lapse. Identified documents were screened for
instructions onmissed doses whichwere categorised according to level of specificity, and cross-referenced to the National Patient
Safety Agency (NPSA) grading of risk of harm from omitted and delayed medicines. Any supporting clinical or pharmacological
evidence was identified from SmPCs.
Results Two thousand two hundred eighty-four documents were identified from 7248 PILs and SmPCs relating to 1501 POMs.
Seven hundred eighty-three (52%) POMs had SmPCs or PILs with no instructions on missed doses; 487 POMs (32%) included
non-specific advice (e.g. “take as soon as possible”); 138 (9%) provided specific instructions; and 93 (6%) referred patients to
seek medical advice. SmPCs for only 13/138 (9%) of those which included specific instructions provided any supporting clinical
or pharmacological evidence. Instructions were absent for several medicines where the NPSA assessed that dose omissions may
result in significant risk of harm.
Conclusions Advice on missed doses is generally inadequate. Pharmaceutical companies and regulatory authorities should
produce clear and concise instructions on what patients should do if they miss doses, with supporting evidence where necessary.
Keywords Medication adherence . Labelling instructions . Patient information leaflets . Compliance
Introduction
Medication non-adherence is highly prevalent, impacts on pa-
tients’ quality of life and survival, and is costly to manage [1].
Adherence is a complex behaviour, which may be
conceptualised in three parts: initiation (which occurs when
the patient takes the first dose), implementation (the extent to
which a patient’s actual dosing corresponds to the prescribed
dosing regimen—from initiation until the last dose), and per-
sistence (the time until the patient stops taking the prescribed
medication) [2]. A common concern of patients who variably
implement their prescribed medicine is what to do when a
regular dose is occasionally delayed or missed [3].
Strict adherence to prescribed medications is important for
achieving therapeutic outcomes, particularly for medicines
which are less “forgiving”, that is, medicines that are associ-
ated with a sudden loss of therapeutic effect when doses are
missed [4]. These drugs are typically associated with a short
elimination half-life and/or have a rapid offset of action in
relation to the dosing interval. Lapses in dosing therefore re-
sult in sub-therapeutic plasma concentrations and periods of
insufficient pharmacologic activity. The often-held assump-
tion that ≥ 80% doses taken represents adequate adherence is
flawed on the basis that drug forgiveness is a function of a
drug’s pharmacokinetic and pharmacodynamic properties and
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is therefore drug-specific [5]. Given that drug forgiveness is
highly variable among different treatments, tailored instruc-
tions regarding the required action if a dose is delayed or
omitted are therefore important [6, 7].
A review of drug labelling in the USA in 2000 found that
58 of the 76 package inserts assessed carried no information
on what patients should do if doses are missed. Adequate
information was provided in only 8 (11%) of cases [8]. The
European Commission guideline on the preparation of
Summaries of Product Characteristics (SmPCs) notes that
where appropriate, advice should be provided on the “action
to be taken if one or more dose(s) is (are) missed” [9]. The
advice should be as specific as possible, taking into consider-
ation the recommended frequency of dosing and relevant
pharmacokinetic data. Patient information leaflets (PILs) have
been a legal requirement as package inserts for all medicines
in the UK since 1999. TheMedicines and Healthcare products
Regulatory Agency advises that information is provided on
“what to do if a dose is missed” [10]. However, this is not
mandatory and the extent to which PILs provide useful infor-
mation for patients is unclear [11].
The aim of the present study was to systematically assess
the PILs and SmPCs of prescription-only medicines with mar-
keting authorisation in the UK to examine the extent to which
they provide appropriate guidance on missed doses to patients
and healthcare professionals.
Methods
We systematically assessed the availability and detailed the
content of instructions for missed doses in the PILs and
SmPCs of all licensed prescription-only medicines catalogued
in the UK electronic Medicines Compendium [12]. The ad-
vanced search feature was used to screen PILs and SmPCs for
missing dose information by using the following keywords:
miss(ed), omit(ted), adhere(d), delay(ed), forgot, forget, lapse.
All available PILs and SmPCs were included in the study
and analysed further if any of the search terms pertained to
instructions onwhat action should be taken if a dose is delayed
or missed (herein denoted as “instructions for missed doses”).
PILs and SmPCs were excluded if they were duplicates (e.g.
multiple generic medicines), or related to different strengths of
the same medicine.
Data on the following items were extracted from docu-
ments which were deemed relevant for inclusion: name of
medicine (brand and generic); date of first marketing authori-
zation; dosage form (oral, oral modified release, parenteral,
topical, eye, ear, inhalation, “other”); dose frequency (less
frequent than once daily, once daily, twice daily, three times
daily, more than three times daily); source of information (PIL
or SmPC); instructions for missed doses; and whether these
instructions were supported by evidence.
All identified instructions for missed doses were
categorised according to the level of detail of the instructions
provided. We defined the following categories: no informa-
tion, referral advice (e.g. “contact your doctor”), generic state-
ment (e.g. “take it as soon as possible”), and specific instruc-
tions (e.g. as specified in an example provided by the
European Medicines Agency [13], below):
“If the patient misses a dose of active substance Xwithin
6 h of the time it is usually taken, the patient should be
told to take it following a meal as soon as possible and
then take the next dose at the regularly scheduled time.
If a patient misses a dose by more than 6 h of the time it
is usually taken, the patient should be told not to take the
missed dose and simply resume the usual dosing
schedule”
The association between the level of detail of the instruc-
tions for missed doses provided, and the decade of first mar-
keting authorization, was tested using a chi-square test.
Instructions for missed doses in PILs and SmPCs were
further assessed with reference to a tool produced by the UK
National Patient Safety Agency (NPSA), which is aimed to
reduce harm from omitted and delayed medicines in UK hos-
pitals [14]. The tool does not list individual medicinal prod-
ucts, but rather, is structured according to British National
Formulary (BNF) legacy chapters and sub-chapters, with each
therapeutic class categorised using a traffic light system for the
risk of harm from a delay or dose omission (Table 1). These
risk categories are assigned to each of three scenarios: (i) dose
not given at the time prescribed, (ii) dose not given within 2 h
of time prescribed, and (iii) dose omitted (i.e. not administered
by the time of next scheduled dose). For the present study, the
highest risk category assigned by the NPSA was selected for
each sub-chapter and was assumed to apply to the medicines
contained therein.
Medicines were subsequently mapped onto NPSA risk cat-
egories to assess the relationship between labelling and the
level of potential harm. To facilitate this mapping exercise,
the Prescription Cost Analysis was used as a database of the
belonging of eachmedicine to a BNF sub-chapter. Limitations
to this approach were that the NPSA does not include all BNF
sub-chapters; and neither does the Prescription Cost Analysis
include all POMs.
The study was undertaken in April 2018 and is reported in
accordance with the ESPACOMP Medication Adherence
Reporting Guideline (EMERGE) [15].
Results
The search yielded 2284 documents from 7248 SmPCs and
PILs relating to 1501 prescription only medicines listed in the
Eur J Clin Pharmacol
electronic Medicines Compendium [12]. Following de-dupli-
cation, 783 (52%) POMs had SmPCs or PILs with no instruc-
tions on missed doses. A total of 685 PILs and 190 SmPCs
relating to 718 unique POMs contained some form of instruc-
tions (Fig. 1). For 93 POMs (representing 6% of all POMs),
these were referral advice; 487 (32% of POMs) had generic
statements; and 138 (9% of POMs) had specific instructions
(Table 2).
Among medicinal products with instructions for missed
doses, the majority (450/718; 62%) were oral formulations,
followed by parenteral formulations (20%), and oral modified
release formulations (4%) (Table 2). Treatments were mainly
for once daily dosing (342/718; 48%). There was moderate
evidence for a relationship between the decade of marketing
authorization and the level of instruction on missed doses
(Chi2 = 21.3; p = 0.046).
The NPSA tool includes 56 BNF legacy sub-chapters that
covered 596 of the 718 POMs which included instructions on
missed doses; and 134 of the 783 POMs that did not. Among the
medicines identified as having instructions on missed doses,
235/718 (33%), 138/718 (19%), 223/718 (31%) were
categorised as “red”, “amber”, and “green” according to
the NPSA report, respectively.
There was no consistent inclusion of instructions for
missed dose in PILs and SmPCs of medicines designated by
the NPSA as having high or moderate risk of adverse out-
comes when doses are delayed or omitted (Table 3). Among
medicines within NPSA categories classed as “red”, 103/338
(25%) had no instructions for missed dose; 31/169 (20%) of
medicines classed as “amber” had no instructions for missed
doses, while 0/223 classed as “green” had no instructions for
missed doses.
Among licensed cardiovascular medicines, a substantial
number of diuretics (12/25; 48%) and beta-adrenoceptor an-
tagonists (5/18; 27%) had no instructions for missed doses.
Oral antidiabetic medicines are categorised as amber risk,
however, less than one fifth (6/35; 17%) had specific instruc-
tions for missed doses.
Among respiratory medicines, the PILs of all bronchodilators
(22/22; 100%) and inhaled corticosteroids (6/6; 100%) had ge-
neric statements (e.g. administer as soon as possible). The PILs
of 80% of medicines for rheumatic disease, which are amber
NPSA risk category, also only included generic statements for
missed doses. Neuropsychiatric medicines for psychoses, parkin-
sonism, and epilepsy, and which are also in the amber risk cate-
gory, had generic statements for missed doses in 21/31 (67%),
19/30 (63%), and 19/26 (73%) of cases, respectively.
Among selected, specialist hospital medicines, all prosta-
glandins and oxytocics had either no or generic statements
(i.e. contact your doctor); yet, the NPSA classed these drugs
Table 1 NPSA categorisation of
risk of harm from omitting or
delaying* a dose of medicine [14]
Risk category Definition
Green: Nil or negligible patient impact with nil or
minor intervention required; no increase in length
of stay
• No or negligible risk of patient impact
• No or minor intervention necessary
• No possibility of an increase in the length
of hospital stay
Amber: Significant short-term patient impact with
moderate intervention required; increase in length
of hospital stay possible
• Risk of significant short-term patient impact (i.e.
significant loss of therapeutic effect, symptom
control, or drug withdrawal effects)
• Subsequent moderate intervention is required
• Resultant long increase (1–15 days) in the length of
hospital stay is possible
Red: Significant or catastrophic long-term patient im-
pact with ongoing intervention required; long in-
crease in length of stay possible
• Risk of significant long-term patient impact (i.e. the
incident, and not the natural progression of illness or
underlying condition, could permanently lessen
bodily functions be they sensory, motor, physio-
logical or intellectual)
• Risk of catastrophic patient impact (i.e. death or
severe irreversible health effects)
• Subsequent ongoing professional intervention
is required
•Resultant very long (> 15 days) increase in the length
of hospital stay is possible
*The omission or delay characteristics considered for each drug or drug class are as specified below:
a) Dose not given at the time prescribed
b) Dose not given within 2 h of time prescribed
c) Dose omitted (i.e. not administered by the time of the next scheduled dose)
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in the red risk category. Similarly, the majority of instructions
for missed doses for cytotoxic agents are generic statements
(13/14; 92%), even though the NPSA report classes anti-
cancer medicines in the highest risk category.
We found evidence on pharmacokinetic and pharmacody-
namic relationships with adherence in the SmPCs of 13/138
(9%) POMs that had specific instructions on missed doses
(Table 4).
2,284 documents containing:
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Discussion
This is the first study to systematically assess the extent and
nature of instructions for missed doses for all UK prescription
only medicines. The study found that for the majority of med-
icines, there were no instructions for missed doses in either
PILs or SmPCs. Moreover, where instructions were provided,
most were generic, and probably inadequate to be informative
to patients or healthcare professionals.
Given the high prevalence of variable implementation
among ambulatory patients and of unintended delayed or
omitted doses in hospitalised patients, the absence of instruc-
tions and widespread use of unspecific instructions provided
to patients, prescribers and pharmacists in PILs and SmPCs is
concerning. Patients recognising an error following self-
administration of a medicine, and seeking information and
reassurance may be complacent if no instructions are provided
in the PIL, and this may lead to harm, especially if the med-
icine is unforgiving. Similarly, medication administration er-
rors are a common occurrence on inpatient hospital wards [16,
17], and knowing what action to take is important for rectify-
ing such errors. The observation that PILs and SmPCs for over
a half of all POMs contained no instructions for missed doses
is alarming, particularly as many of these are considered to be
in high-risk categories by the NPSA.
Harm from delayed or omitted doses can result from re-
duced effectiveness or onset of adverse events, and is a func-
tion of a medicine’s forgiveness, efficacy and clinical indica-
tion. Manufacturers are not required to submit evidence on
drug forgiveness to regulators, but while SmPCs provide es-
sential data on the clinical pharmacology and adverse reac-
tions of medicines, prescribers may not be sufficiently well
informed to make specific recommendations to patients who
enquire about missed doses. The extent to which medicines
are forgiving to missed doses cannot be assumed from their
pharmacokinetics, as forgiveness is also a function of drug
pharmacodynamics [4, 5]. Aspirin, as one example, has a
short elimination half-life, in the order of 2–3 h. However,
the duration of antiplatelet effect does not correlate with the
presence of salicylic acid in the circulation. Aspirin’s irrevers-
ible acetylation of platelet cyclo-oxygenase, coupled with the
inability of platelets to synthesise new cyclo-oxygenase,
means that the post-dose duration of action (forgiveness) is
7–10 days [18]. Missing occasional doses is largely inconse-
quential. Rivaroxaban and edoxaban have a longer plasma
half-life (~ 12–14 h), but a rapid offset of effect (~ 1 day)
owing to reversible inhibition of factor Xa which is closely
correlated with their plasma concentrations. These are less
forgiving to delayed and missed doses, and more likely to
result in under anticoagulation and the associated risk of
thrombosis in patients who poorly implement their dosing
[7]. The SmPC for rivaroxaban [19]—but not edoxaban
[20]—includes clear and specific instructions on missed
doses. However, the details provided in the PILs for both
drugs are very limited.
Among the SmPCs which provided explicit instructions
for missed doses, some made reference to simulation, phar-
macokinetic or clinical studies that provided supportive evi-
dence. A range of methods are available to inform strategies
on mitigating the effects of missed doses. Clinical trials de-
signed to estimate the post-dose duration of action include
substituting a single (or serial) dose(s) with placebo(s). In
the case of oral contraceptives, this was done to define the
interval between a last-taken pill before the ovulation-
inducing surge of pituitary gonadotrophins appeared [21].
Similar studies have been performed with antihypertensive
drugs [22–30] which indicate, for instance, amlodipine to be
more forgiving than either enalapril or diltiazem, and to be
more forgiving when combined with olmesartan than with
perindopril [31]. For warfarin, pharmacokinetic-
pharmacodynamic models have been proposed to inform la-
belling recommendations [32], and population pharmacoki-
netic models have been used to simulate missed doses of
Table 2 Characteristics of the POMs and data sources analysed
Characteristics of results Number (%)
Instructions for missed doses (out of all 1501 POMs)
No instructions 783 (52)
Referral statements 93 (6)
Generic statements 487 (32)
Specific instructions 138 (9)
Source of information (out of 718)
PIL 528 (73)
PIL and SmPC 157 (22)
SmPC 33 (5)
Dosage form (out of 718)
Oral (immediate release) 450 (62)
Parenteral 144 (20)
Inhalation 30 (4)
Oral (modified release formulation) 29 (4)
Sensory (Eye and ear) 29 (4)
Topical 24 (3)
Other 12 (2)
Dosage frequency (out of 718)
Less than once daily 86 (12)
Once daily 342 (48)
Twice daily 165 (23)
Three times daily 86 (12)
More than 3 times daily 39 (5)
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Table 3 Level of detail provided in instructions on missed doses for NPSA moderate/high risk category POMmedicines. Data (number of medicines)
are presented by BNF sub-section, with corresponding NPSA categorisation for the highest risk drug within each sub-section










Chapter 1: Gastro-intestinal system
Antisecretory drugs and mucosal protectants 2 0 5 0 Amber
Chronic bowel disorders 1 0 10 0 Amber
Chapter 2: Cardiovascular system
Positive inotropic drugs 1 0 2 0 Red
Diuretics 12 1 13 0 Red
Anti-arrhythmics 1 2 6 0 Red
Beta-adrenoceptor antagonists 5 0 13 0 Amber
Antihypertensives and heart failure 1 0 5 0 Red
Nitrates, calcium channel blockers, other antianginal drugs 1 0 5 1 Red
Sympathomimetics 3 0 0 0 Red
Anticoagulants and protamine 5 2 5 3 Red
Antiplatelet 3 0 4 1 Red
Stable angina, acute coronary syndrome, fibrinolysis 3 0 0 0 Red
Antifibrinolytics and hameostatics 0 0 1 0 Red
Chapter 3: Respiratory system
Bronchodilators 0 0 22 0 Red
Corticosteroids 0 0 6 0 Red
Antihistamines, hyposensitisation and allergic emergencies 5 2 14 0 Red
Chapter 4: Central nervous system
Anxiolytics 14 0 4 2 Red
Drugs used in psychoses 3 4 21 2 Amber
Analgesics 13 2 19 5 Red
Antiepileptic drugs 4 4 19 3 Red
Parkinsonism drugs 4 0 19 3 Red
Drugs used in substance dependence 0 2 8 1 Amber
Drugs for dementia 2 0 3 0 Amber
Chapter 6: Endocrine system
Short acting insulins 0 0 4 0 Red
Intermediate- and long-acting insulins 2 0 7 0 Amber
Oral antidiabetic 1 0 28 6 Amber
Treatment of hypoglycaemia 0 0 1 0 Red
Replacement corticosteroids therapy 0 0 1 0 Red
Glucocorticoid therapy 2 2 6 0 Amber
Posterior pituitary hormones and antagonists 0 1 1 0 Red
Drugs affecting gonadotrophins 0 0 5 0 Red
Chapter 7: Obstetrics, gynaecology, and urinary-tract disorders
Prostaglandins and oxytocics 2 1 0 0 Red
Ductus arteriousus 1 0 0 0 Red
Mifepristone 1 0 0 0 Red
Myometrial relaxants 2 0 0 0 Red
Emergency contraception 0 0 0 2 Red
Drugs used in urological pain 4 0 0 0 Amber
Bladder instillations and urological surgery 1 0 0 0 Amber
Chapter 8: Malignant disease and immunosuppression
Alkylating agents, anthracyclines and other cytotoxic antibiotics,
antimetabolites, other antineoplastic drugs
1 5 7 1 Red
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eslicarbazepine in patients with partial-onset seizures [33].
Pharmacometric analyses have also been used for a range of
psychoactive treatments [34], and ought to be performed rou-
tinely to provide evidence for PIL and SmPC instructions on
missed doses; especially for less forgiving treatments.
In our study, less than one tenth of UK POMs provided
specific instruction on missed doses. These included medi-
cines for neuropsychiatric disorders, type 2 diabetes as well
as oral contraceptives and anticoagulants. A previous study
in USA, reviewed the package inserts of 168 medicines
found that only 8% had adequate information regarding
medication adherence, while the majority (58%) had no in-
formation at all [8]. Our findings, that 52% of medicines
have no information regarding missing dose instruction are
consistent, but also reveal no change in practice over two
decades. However, we recognise that SmPCs may not be
updated in several respects, and our analysis suggests that
medicines with more recent marketing authorisation provide
better information.
Our study benefited from being systematic and including
all prescription only medicines indexed in the electronic
Medicines Compendium. However, there were some
limitations. Specifically, the eMC is not complete—not all
pharmaceutical companies subscribe to Datapharm to publish
their information on the eMC website, and so a small propor-
tion of medicines licensed in the UK will not have been in-
cluded. We were also constrained by the advanced search
facility of the eMC, which provided limited flexibility for
searching, especially within portable document format (pdf)
files, which represented many PILs. Our search may also have
lacked sensitivity through the omission of potentially relevant
search terms. Nevertheless, we considered that the study was
conducted robustly with sampling that was sufficiently reflec-
tive of UK licensed POMs without any systematic bias.
Finally, the classification of medicines in the NPSA tool is
based on consensus of the opinions of pharmacists and patient
safety specialists, and validated by an expert panel. It focuses
primarily on the use of medicines in hospitals with indications
deemed of particular relevance for primary care not having
been considered. It also does not have full coverage of BNF
sub-chapters, and therefore excluded 771/1501 (51%) of eMC
listed medicines. Most of these (649/771; 84%) had no in-
structions on missed doses, suggesting the NPSA tool may
select for high risk medicines, as might be expected.
Table 3 (continued)










Vinca alkaloids and etoposide 6 1 0 0 Red
Drugs affecting the immune response 0 0 7 0 Red
Sex hormones and hormone antagonists in malignant
disease-depot preparations
1 4 12 2 Red
Chapter 9: Nutrition and blood
Anaemias and some other blood disorders 0 4 2 0 Amber
Fluids and electrolytes 0 1 4 0 Red
Minerals 5 0 8 0 Red
Vitamin B group 2 0 0 0 Red
Vitamin K 2 0 1 1 Red
Chapter 10: Musculoskeletal and joint diseases
Local corticosteroid injections 4 0 0 0 Amber
Drugs for rheumatic disease 0 1 12 2 Amber
Gout and cytotoxic-induced hyperuricaemia 3 0 3 0 Amber
Chapter 11: Eye
Corticosteroids 5 0 16 0 Red
Mydriatics and cycloplegics 2 0 2 0 Red
Treatment of glaucoma 2 0 19 2 Red
Miscellaneous ophthalmic preparations 1 0 7 0 Red
Chapter 13: Skin
Preparations for eczema and psoriasis 1 0 1 0 Amber
Sunscreens and camouflagers 0 0 2 0 Amber
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Table 4 Clinical and
pharmacological information
relating to duration of effect or to
missed doses, as presented in the
SmPCs
Drug name Information on duration of effect or relating to missed doses
Acenocoumarol The anticoagulant effect persists beyond 24 h
Amiodarone It is strongly protein bound and has an average plasma half-life of 50
days (reported range 20–100 days). It follows that sufficient time
must be allowed for a new distribution equilibrium to be achieved
between adjustments of dosage. In patients with potentially lethal
arrhythmias the long half-life is a valuable safeguard, as omission of
occasional doses does not significantly influence the overall thera-
peutic effect. It is particularly important that the minimum effective
dosage is used and the patient is monitored regularly to detect the
clinical features of excess amiodarone dosage. Therapy may then be
adjusted accordingly.
Atenolol Effective for at least 24 h after a single oral dose. The drug facilitates
compliance by its acceptability to patients and simplicity of dosing.
Atenolol, chlortalidone It is effective for at least 24 h after a single oral daily dose.
This simplicity of dosing facilitates compliance by its acceptability
to patients.
Ethinylestradiol, norelgestromin Results from an EVRA study of extended wear of single contraceptive
transdermal patch for 7 days and 10 days indicated that target Css of
norelgestromin and ethinyl estradiol weremaintained during a 3-day
period of extended wear of EVRA (10 days). These findings suggest
that clinical efficacy would be maintained even if a scheduled
change is missed for as long as 2 full days
Human normal immunoglobulin Simulation of 2–3 missed daily doses resulted in a median serum IgG
level decrease of ≤ 4% compared with consistent daily dosing. By
replacing the missed doses when daily dosing was resumed, the
median concentration profile recovered within 2 to 3 days.
However, if missed doses were not replaced when dosing was
resumed, it took up to 5–6 weeks for the IgG trough levels to return
to steady-state
Insulin degludec On occasions when administration at the same time of the day is not
possible, Tresiba allows for flexibility in the timing of insulin
administration. A minimum of 8 h between injections should
always be ensured. There is no clinical experience with flexibility in
dosing time of Tresiba in children and adolescents. Patients who
forget a dose are advised to take it upon discovery and then resume
their usual once-daily dosing schedule
Leuprorelin The therapy is a long-term treatment, adjusted individually. PROSTAP
3 should be administered as precisely as possible in regular
3-monthly periods. An exceptional delay of the injection date for a
few days (90 ± 2 days) does not influence the results of the therapy
Levonorgestrel, ethinylestradio The efficacy of combined oral contraceptives may be reduced, in the
event of missed tablets, vomiting or diarrhoea, or concomitant
medication
Neostigmine The usual duration of action of a dose is 2 to 4 h
Perampanel Single missed dose: As perampanel has a long half-life, the patient
should wait and take their next dose as scheduled. If more than 1
dose has been missed, for a continuous period of less than 5
half-lives (3 weeks for patients not taking perampanel
metabolism-inducing anti-epileptic drugs (AED), 1 week for pa-
tients taking perampanel metabolism-inducing AEDs), consider-
ation should be given to re-start treatment from the last dose level. If
a patient has discontinued perampanel for a continuous period of
more than 5 half-lives, it is recommended that initial dosing rec-
ommendations given above should be followed.
Terbutaline The duration of action of a single dose is up to 6 h
Valsartan hydrochlorothiazide The antihypertensive effect is substantially present within 2 weeks. In
most patients, maximal effects are observed within 4 weeks.
However, in some patients, 4–8 weeks treatment may be required.
This should be taken into account during dose titration.
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In conclusion, the high prevalence of non-adherence to
medications, particularly in the form of variable implementa-
tion and its associated hazards, requires that patients and
healthcare professionals need to be suitably informed on what
actions to take when doses are delayed or missed. Patients
often face a dilemma on what to do when they miss a dose,
and while patient information leaflets and summaries of prod-
ucts characteristics are considered key references, the advice
currently offered in these resources is largely inadequate. We
recommend that further regulatory oversight is warranted, to
ensure the safeguard of patients through the provision of ap-
propriate information. This is especially important for less
forgiving medicines, where specific trials or simulations may
be necessary to provide the relevant evidence.
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